Abstract: Egg laying birds on egg farms are inoculated with one or more disease antigens from microbial organisms causing infectious diseases. Egg material from the eggs contain one or more avian antibodies against the microbial organisms and these avian antibodies can specifically bind and/or neutralize the microbial organisms upon consumption by individuals in a population. Egg products comprising the one or more avian antibodies are provided to individuals in the population to increase the prevalence of avian antibodies against the microbial organism in the population. The egg products are provided in a variety of formulations for protecting individuals against the disease and/or for reducing the susceptibility for acquiring the disease. Egg products effective against infections of SARS-CoV-2 in individuals and for reducing the incidence of Covid-19 are provided. Methods are provided to decrease the infection rates of infectious diseases in a population of individuals.

Abstract: Facemasks with an integrated vims detection system are described. The virus detection system is embedded in or on a acemask worn by an individual susceptible to a viral infection. The individual wears a facemask for protective purposes during work or leisure. If the individual develops a viral infection and begins discharging viral particles from mouth and/or nose, the vims detection system embedded in the facemask retains the virus particles. The virus particles are detected in an immunoassay. The virus particles in the virus detection system embedded in the facemask are detected by avian antibodies. The virus detection system in the facemask is configured to detect one or more viruses, for example, SARS-CoV-2.

Abstract: Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.